Blue Earth Diagnostics

Blue Earth Diagnostics is a leading molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide the care of cancer patients. Blue Earth Diagnostics was founded in 2014 and is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company's first approved and commercially available product is Axumin™ (fluciclovine F 18), a novel molecular imaging agent approved in the United States and the European Union for PET imaging to detect and locate prostate cancer in men diagnosed with biochemical recurrence.In May 2018, Blue Earth Diagnostics expanded its prostate cancer portfolio by acquiring global exclusive rights to a broad range of prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical ("rh") cancer drugs. rhPSMA is a clinical-stage, investigational class of theranostic compounds with potential applications in the imaging and treatment of prostate cancer.